The role of stem/progenitor cells and wnt/β-catenin signaling pathway in the patients with prostate cancer

Simple item page
dc.contributor.authorVatansever H.S.
dc.contributor.authorGumus B.
dc.contributor.authorAydogdu O.
dc.contributor.authorSivrikoz O.N.
dc.contributor.authorTürkôz-Uluer E.
dc.contributor.authorKivanç M.
dc.contributor.authorAteşçi Y.Z.
dc.contributor.authorBugdayci H.
dc.date.accessioned2024-07-22T08:14:44Z
dc.date.available2024-07-22T08:14:44Z
dc.date.issued2014
dc.description.abstractAim: The aim of this paper was to investigate the possible effect of cancer stem cells (CSCs) and relationship with Wnt/β-catenin signaling pathway progressing of prostate cancer. Methods: Thirty men with a pathological diagnosis of benign prostate hyperplasia (BPH) (group 1, N.=10), prostate cancer with a gleason score of ≤6 (group 2, N.=10), and prostate cancer with a gleason score of >6 (group 3, N.=10) were included in the study. The patients' groups were compared in terms of immunoreactivity strength of prostatic stem/progenitor cell surface markers including CD133 and CD117. We also compared the immunoreactivity of Wnt7a, a part of Wnt signaling pathway which has a potential role in the progression of several cancers including prostate cancer. The immunoreactivity of Frizzled 6 (Fzd 6) which is the receptor of Wnt family was also evaluated in all groups. Results: Immunohistochemical analyses demonstrated that although CD 133 immunoreactivity was positive in all groups, immunoreactivity was significantly stronger in group 3 when compared to other groups. While CD117 immunoreactivity was negative in group 1 and 2, it was positive in group 3. Wnt7a immunoreactivity was weak in all groups and Fzd 6 immunoreactivity was stronger in group 1 and 3 when compared to group 2. Conclusion: Our findings demonstrated that CSCs and Wnt signaling pathway have a potential role in the development and progression of prostate cancer.
dc.identifier.issn03932249
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/16645
dc.language.isoEnglish
dc.publisherEdizioni Minerva Medica
dc.subjectHumans
dc.subjectMale
dc.subjectProstatic Neoplasms
dc.subjectStem Cells
dc.subjectWnt Signaling Pathway
dc.subjectbeta catenin
dc.subjectCD133 antigen
dc.subjectfrizzled 6 protein
dc.subjectfrizzled protein
dc.subjectstem cell factor receptor
dc.subjectunclassified drug
dc.subjectWnt protein
dc.subjectWnt7a protein
dc.subjectArticle
dc.subjectcancer growth
dc.subjectcancer stem cell
dc.subjectclinical article
dc.subjectGleason score
dc.subjecthuman
dc.subjecthuman tissue
dc.subjectimmunohistochemistry
dc.subjectimmunoreactivity
dc.subjectmale
dc.subjectprostate cancer
dc.subjectprostate hypertrophy
dc.subjectWnt signaling pathway
dc.subjectpathology
dc.subjectphysiology
dc.subjectProstatic Neoplasms
dc.subjectstem cell
dc.subjectWnt signaling pathway
dc.titleThe role of stem/progenitor cells and wnt/β-catenin signaling pathway in the patients with prostate cancer
dc.typeArticle

Files

Collections

Scopus Koleksiyonu